$TRU
TransUnion

2021 Q1 Form 10-Q Financial Statement

#000155203321000029 Filed on April 27, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $698.9M $639.6M
YoY Change 9.27% 3.28%
Cost Of Revenue $243.2M $225.1M
YoY Change 8.04% 8.17%
Gross Profit $502.1M $462.5M
YoY Change 8.56% 12.48%
Gross Profit Margin 71.84% 72.31%
Selling, General & Admin $219.1M $235.4M
YoY Change -6.92% 20.29%
% of Gross Profit 43.64% 50.9%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $94.30M $90.30M
YoY Change 4.43% -3.42%
% of Gross Profit 18.78% 19.52%
Operating Expenses $535.3M $550.8M
YoY Change -2.81% 10.78%
Operating Profit $163.6M $120.6M
YoY Change 35.66% -1.23%
Interest Expense $25.80M $37.70M
YoY Change -31.56% -16.22%
% of Operating Profit 15.77% 31.26%
Other Income/Expense, Net -$22.50M -$40.20M
YoY Change -44.03% -13.55%
Pretax Income $141.0M $96.60M
YoY Change 45.96% 27.95%
Income Tax $23.70M $22.30M
% Of Pretax Income 16.81% 23.08%
Net Earnings $127.9M $70.20M
YoY Change 82.19% -0.99%
Net Earnings / Revenue 18.3% 10.98%
Basic Earnings Per Share $0.67 $0.37
Diluted Earnings Per Share $0.66 $0.37
COMMON SHARES
Basic Shares Outstanding 190.9M shares 189.2M shares
Diluted Shares Outstanding 192.5M shares 192.2M shares

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $436.3M $318.9M
YoY Change 36.81% 32.21%
Cash & Equivalents $433.0M $305.7M
Short-Term Investments $3.300M $13.20M
Other Short-Term Assets $202.3M $151.1M
YoY Change 33.88% -9.25%
Inventory
Prepaid Expenses $115.7M $83.40M
Receivables $488.1M $468.0M
Other Receivables $0.00 $36.60M
Total Short-Term Assets $1.123B $924.8M
YoY Change 21.47% 3.54%
LONG-TERM ASSETS
Property, Plant & Equipment $215.0M $210.0M
YoY Change 2.38% -2.1%
Goodwill $3.455B $3.278B
YoY Change 5.41% -2.28%
Intangibles $2.243B $2.287B
YoY Change -1.94% -8.98%
Long-Term Investments $47.00M $42.40M
YoY Change 10.85% -11.3%
Other Assets $251.7M $233.4M
YoY Change 7.84% 16.0%
Total Long-Term Assets $6.164B $6.008B
YoY Change 2.6% -4.37%
TOTAL ASSETS
Total Short-Term Assets $1.123B $924.8M
Total Long-Term Assets $6.164B $6.008B
Total Assets $7.288B $6.933B
YoY Change 5.12% -3.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $203.5M $187.1M
YoY Change 8.77% 8.91%
Accrued Expenses $46.90M $25.30M
YoY Change 85.38% 43.75%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $62.70M $58.60M
YoY Change 7.0% -25.82%
Total Short-Term Liabilities $630.2M $555.5M
YoY Change 13.45% 1.76%
LONG-TERM LIABILITIES
Long-Term Debt $3.293B $3.586B
YoY Change -8.15% -9.27%
Other Long-Term Liabilities $193.2M $211.7M
YoY Change -8.74% 74.1%
Total Long-Term Liabilities $3.487B $3.797B
YoY Change -8.18% -6.78%
TOTAL LIABILITIES
Total Short-Term Liabilities $630.2M $555.5M
Total Long-Term Liabilities $3.487B $3.797B
Total Liabilities $4.525B $4.769B
YoY Change -5.12% -6.48%
SHAREHOLDERS EQUITY
Retained Earnings $1.051B $707.7M
YoY Change 48.48% 68.98%
Common Stock $2.119B $2.040B
YoY Change 3.86% 3.58%
Preferred Stock
YoY Change
Treasury Stock (at cost) $243.8M $211.8M
YoY Change 15.11% 19.66%
Treasury Stock Shares 5.500M shares 5.200M shares
Shareholders Equity $2.666B $2.068B
YoY Change
Total Liabilities & Shareholders Equity $7.288B $6.933B
YoY Change 5.12% -3.38%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income $127.9M $70.20M
YoY Change 82.19% -0.99%
Depreciation, Depletion And Amortization $94.30M $90.30M
YoY Change 4.43% -3.42%
Cash From Operating Activities $144.8M $125.5M
YoY Change 15.38% 1.37%
INVESTING ACTIVITIES
Capital Expenditures $40.70M $42.00M
YoY Change -3.1% 0.24%
Acquisitions
YoY Change
Other Investing Activities $400.0K -$2.500M
YoY Change -116.0% -213.64%
Cash From Investing Activities -$71.90M -$25.50M
YoY Change 181.96% -49.9%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $10.10M $10.90M
YoY Change -7.34% 7.92%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -$132.2M -$49.70M
YoY Change 166.0% -17.03%
NET CHANGE
Cash From Operating Activities $144.8M $125.5M
Cash From Investing Activities -$71.90M -$25.50M
Cash From Financing Activities -$132.2M -$49.70M
Net Change In Cash -$59.90M $31.60M
YoY Change -289.56% 134.07%
FREE CASH FLOW
Cash From Operating Activities $144.8M $125.5M
Capital Expenditures $40.70M $42.00M
Free Cash Flow $104.1M $83.50M
YoY Change 24.67% 1.95%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001552033
CY2021Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000.0 shares
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000.0 shares
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q1 dei Document Type
DocumentType
10-Q
CY2021Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q1 dei Document Period End Date
DocumentPeriodEndDate
2021-03-31
CY2021Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q1 dei Entity File Number
EntityFileNumber
001-37470
CY2021Q1 dei Entity Registrant Name
EntityRegistrantName
TransUnion
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
61-1678417
CY2021Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
555 West Adams,
CY2021Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Chicago,
CY2021Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
IL
CY2021Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
60661
CY2021Q1 dei City Area Code
CityAreaCode
312
CY2021Q1 dei Local Phone Number
LocalPhoneNumber
985-2000
CY2021Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value
CY2021Q1 dei Trading Symbol
TradingSymbol
TRU
CY2021Q1 dei Security Exchange Name
SecurityExchangeName
NYSE
CY2021Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2021Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2021Q1 us-gaap Other Assets Current
OtherAssetsCurrent
202300000 USD
CY2021Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021Q1 dei Entity Shell Company
EntityShellCompany
false
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
191300000 shares
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
433000000.0 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
493000000.0 USD
CY2021Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
26900000 USD
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
26600000 USD
CY2021Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
488100000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
453700000 USD
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
159500000 USD
CY2021Q1 us-gaap Assets Current
AssetsCurrent
1123400000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
1106200000 USD
CY2021Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
582400000 USD
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
548900000 USD
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
215000000.0 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
223200000 USD
CY2021Q1 us-gaap Goodwill
Goodwill
3454800000 USD
CY2020Q4 us-gaap Goodwill
Goodwill
3461500000 USD
CY2021Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1799800000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1752200000 USD
CY2021Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2242700000 USD
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2284600000 USD
CY2021Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
251700000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
236100000 USD
CY2021Q1 us-gaap Assets
Assets
7287600000 USD
CY2020Q4 us-gaap Assets
Assets
7311600000 USD
CY2021Q1 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
203500000 USD
CY2020Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
193200000 USD
CY2021Q1 us-gaap Debt Current
DebtCurrent
62700000 USD
CY2020Q4 us-gaap Debt Current
DebtCurrent
55500000 USD
CY2021Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
364000000.0 USD
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
415800000 USD
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
630200000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
664500000 USD
CY2021Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
3293300000 USD
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
3398700000 USD
CY2021Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
407800000 USD
CY2020Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
396800000 USD
CY2021Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
193200000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
215500000 USD
CY2021Q1 us-gaap Liabilities
Liabilities
4524500000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
4675500000 USD
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000.0 shares
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
196800000 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
195700000 shares
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
191300000 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
190500000 shares
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
2000000.0 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
2000000.0 USD
CY2021Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2116800000 USD
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2088100000 USD
CY2021Q1 us-gaap Treasury Stock Shares
TreasuryStockShares
5500000 shares
CY2020Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
5200000 shares
CY2021Q1 us-gaap Treasury Stock Value
TreasuryStockValue
243800000 USD
CY2020Q4 us-gaap Treasury Stock Value
TreasuryStockValue
215200000 USD
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
1050800000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
937400000 USD
CY2021Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-260300000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-272100000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
2665500000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
2540200000 USD
CY2021Q1 us-gaap Minority Interest
MinorityInterest
97600000 USD
CY2020Q4 us-gaap Minority Interest
MinorityInterest
95900000 USD
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
2763100000 USD
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
2636100000 USD
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7287600000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7311600000 USD
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
745300000 USD
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
687600000 USD
CY2021Q1 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
243200000 USD
CY2020Q1 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
225100000 USD
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
227200000 USD
CY2020Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
235400000 USD
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
94300000 USD
CY2020Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
90300000 USD
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
564600000 USD
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
550800000 USD
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
180700000 USD
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
136800000 USD
CY2021Q1 us-gaap Interest Expense
InterestExpense
25800000 USD
CY2020Q1 us-gaap Interest Expense
InterestExpense
37700000 USD
CY2021Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
700000 USD
CY2020Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1900000 USD
CY2021Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
3000000.0 USD
CY2020Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
2600000 USD
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-400000 USD
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-7000000.0 USD
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-22500000 USD
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-40200000 USD
CY2021Q1 us-gaap Income Loss Including Portion Attributable To Noncontrolling Interest
IncomeLossIncludingPortionAttributableToNoncontrollingInterest
158200000 USD
CY2020Q1 us-gaap Income Loss Including Portion Attributable To Noncontrolling Interest
IncomeLossIncludingPortionAttributableToNoncontrollingInterest
96600000 USD
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
27500000 USD
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
22300000 USD
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
192200000 shares
CY2021Q1 us-gaap Profit Loss
ProfitLoss
130600000 USD
CY2020Q1 us-gaap Profit Loss
ProfitLoss
74300000 USD
CY2021Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
2700000 USD
CY2020Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
4100000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
127900000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
70200000 USD
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
190900000 shares
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
189200000 shares
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
192500000 shares
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.67
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.37
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.66
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.37
CY2021Q1 us-gaap Profit Loss
ProfitLoss
130600000 USD
CY2020Q1 us-gaap Profit Loss
ProfitLoss
74300000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
-10900000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
-183000000.0 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-300000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-400000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-10600000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-182600000 USD
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax
0 USD
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax
-500000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Derivatives Qualifying As Hedges Before Tax
OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax
28300000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Derivatives Qualifying As Hedges Before Tax
OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax
-46900000 USD
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax
7000000.0 USD
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax
-11700000 USD
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
21300000 USD
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
-35700000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
10700000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-218300000 USD
CY2021Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
141300000 USD
CY2020Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-144000000.0 USD
CY2021Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
1700000 USD
CY2020Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
2400000 USD
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
139600000 USD
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-146400000 USD
CY2021Q1 us-gaap Profit Loss
ProfitLoss
130600000 USD
CY2020Q1 us-gaap Profit Loss
ProfitLoss
74300000 USD
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
94300000 USD
CY2020Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
90300000 USD
CY2021Q1 us-gaap Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
500000 USD
CY2020Q1 us-gaap Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
1800000 USD
CY2021Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
4000000.0 USD
CY2020Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-600000 USD
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
17900000 USD
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4900000 USD
CY2021Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1100000 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
12300000 USD
CY2020Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
6200000 USD
CY2021Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
500000 USD
CY2020Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
1300000 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
35300000 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
40600000 USD
CY2021Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
23400000 USD
CY2020Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
500000 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
7200000 USD
CY2021Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-51600000 USD
CY2020Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-20300000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
144800000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
125500000 USD
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
43200000 USD
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
42000000.0 USD
CY2021Q1 us-gaap Proceeds From Sale Of Other Investments
ProceedsFromSaleOfOtherInvestments
1500000 USD
CY2020Q1 us-gaap Proceeds From Sale Of Other Investments
ProceedsFromSaleOfOtherInvestments
19400000 USD
CY2021Q1 us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
19800000 USD
CY2020Q1 us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
200000 USD
CY2021Q1 us-gaap Payments To Acquire Businesses And Interest In Affiliates
PaymentsToAcquireBusinessesAndInterestInAffiliates
10000000.0 USD
CY2020Q1 us-gaap Payments To Acquire Businesses And Interest In Affiliates
PaymentsToAcquireBusinessesAndInterestInAffiliates
5200000 USD
CY2021Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
400000 USD
CY2020Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-2500000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-71900000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-25500000 USD
CY2021Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
99600000 USD
CY2020Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
13800000 USD
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10100000 USD
CY2020Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10900000 USD
CY2021Q1 us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
15000000.0 USD
CY2020Q1 us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
14700000 USD
CY2021Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
27700000 USD
CY2021Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1600000 USD
CY2020Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3000000.0 USD
CY2020Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
32100000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-132200000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-49700000 USD
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-700000 USD
CY2020Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-18700000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-60000000.0 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
31600000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
493000000.0 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
274100000 USD
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
433000000.0 USD
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
305700000 USD
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
26600000 USD
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
19000000.0 USD
CY2021Q1 us-gaap Allowance For Doubtful Accounts Receivable Period Increase Decrease
AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease
1100000 USD
CY2020Q1 us-gaap Allowance For Doubtful Accounts Receivable Period Increase Decrease
AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease
6200000 USD
CY2021Q1 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
800000 USD
CY2020Q1 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
2000000.0 USD
CY2021Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
26900000 USD
CY2020Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
23200000 USD
CY2021Q1 us-gaap Business Combination Contingent Consideration Arrangements Range Of Outcomes Value High
BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
44100000 USD
CY2021Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
115700000 USD
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
84700000 USD
CY2021Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
3300000 USD
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
3200000 USD
CY2021Q1 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
1200000 USD
CY2020Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
1800000 USD
CY2021Q1 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
82100000 USD
CY2020Q4 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
69800000 USD
CY2021Q1 us-gaap Other Assets Current
OtherAssetsCurrent
202300000 USD
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
159500000 USD
CY2021Q1 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
139900000 USD
CY2020Q4 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
138800000 USD
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
64400000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
65600000 USD
CY2021Q1 us-gaap Interest Rate Derivative Assets At Fair Value
InterestRateDerivativeAssetsAtFairValue
4400000 USD
CY2020Q4 us-gaap Interest Rate Derivative Assets At Fair Value
InterestRateDerivativeAssetsAtFairValue
0 USD
CY2021Q1 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
43000000.0 USD
CY2020Q4 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
31700000 USD
CY2021Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
251700000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
236100000 USD
CY2021Q1 us-gaap Equity Method Investments
EquityMethodInvestments
47000000.0 USD
CY2020Q4 us-gaap Equity Method Investments
EquityMethodInvestments
46100000 USD
CY2021Q1 ck0001552033 Nonmarketableequitysecurities
Nonmarketableequitysecurities
92900000 USD
CY2020Q4 ck0001552033 Nonmarketableequitysecurities
Nonmarketableequitysecurities
92700000 USD
CY2021Q1 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
139900000 USD
CY2020Q4 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
138800000 USD
CY2021Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
3000000.0 USD
CY2020Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
2600000 USD
CY2021Q1 us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
600000 USD
CY2020Q1 us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
600000 USD
CY2021Q1 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
92600000 USD
CY2020Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
149300000 USD
CY2021Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
92100000 USD
CY2020Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
85500000 USD
CY2021Q1 us-gaap Litigation Reserve Current
LitigationReserveCurrent
79500000 USD
CY2020Q4 us-gaap Litigation Reserve Current
LitigationReserveCurrent
76000000.0 USD
CY2021Q1 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
38800000 USD
CY2020Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
37800000 USD
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
14100000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
17900000 USD
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
46900000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
49300000 USD
CY2021Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
364000000.0 USD
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
415800000 USD
CY2021Q1 us-gaap Interest Rate Derivative Liabilities At Fair Value
InterestRateDerivativeLiabilitiesAtFairValue
65700000 USD
CY2020Q4 us-gaap Interest Rate Derivative Liabilities At Fair Value
InterestRateDerivativeLiabilitiesAtFairValue
89700000 USD
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
57100000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
54000000.0 USD
CY2021Q1 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
34800000 USD
CY2020Q4 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
34400000 USD
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000.0 shares
CY2021Q1 ck0001552033 Other Noncurrent Other Liabilities
OtherNoncurrentOtherLiabilities
34000000.0 USD
CY2020Q4 ck0001552033 Other Noncurrent Other Liabilities
OtherNoncurrentOtherLiabilities
34400000 USD
CY2021Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
193200000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
215500000 USD
CY2021Q1 us-gaap Debt And Capital Lease Obligations
DebtAndCapitalLeaseObligations
3356000000.0 USD
CY2020Q4 us-gaap Debt And Capital Lease Obligations
DebtAndCapitalLeaseObligations
3454200000 USD
CY2021Q1 us-gaap Debt Current
DebtCurrent
62700000 USD
CY2020Q4 us-gaap Debt Current
DebtCurrent
55500000 USD
CY2021Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
3293300000 USD
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
3398700000 USD
CY2021Q1 us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
85000000.0 USD
CY2021Q1 us-gaap Write Off Of Deferred Debt Issuance Cost
WriteOffOfDeferredDebtIssuanceCost
500000 USD
CY2021Q1 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
100000 USD
CY2021Q1 ck0001552033 Incremental Borrowings Amount
IncrementalBorrowingsAmount
1000000000.0 USD
CY2021Q1 ck0001552033 Incremental Borrowings Criteria Percentageof Consolidated Ebitda
IncrementalBorrowingsCriteriaPercentageofConsolidatedEBITDA
1
CY2021Q1 ck0001552033 Incremental Borrowings Criteria Senior Secured Leverageratio
IncrementalBorrowingsCriteriaSeniorSecuredLeverageratio
4.25
CY2021Q1 ck0001552033 Net Leverage Ratio Requirement
NetLeverageRatioRequirement
5.5
CY2021Q1 ck0001552033 Covenant Dividend Restriction Amount
CovenantDividendRestrictionAmount
75000000 USD
CY2021Q1 ck0001552033 Covenant Dividend Restriction Percentageof Consolidated Ebitda
CovenantDividendRestrictionPercentageofConsolidatedEBITDA
0.075
CY2021Q1 ck0001552033 Net Leverage Ratio Requirement Dividends
NetLeverageRatioRequirementDividends
4.75
CY2021Q1 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.075
CY2021Q1 us-gaap Dividends Payable Date Declared Day Month And Year
DividendsPayableDateDeclaredDayMonthAndYear
2021-02-24
CY2021Q1 us-gaap Dividends Payable Date Of Record Day Month And Year
DividendsPayableDateOfRecordDayMonthAndYear
2021-03-11
CY2021Q1 us-gaap Dividend Payable Date To Be Paid Day Month And Year
DividendPayableDateToBePaidDayMonthAndYear
2021-03-26
CY2017Q1 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
300000000.0 USD
us-gaap Stock Repurchase Program Period In Force1
StockRepurchaseProgramPeriodInForce1
P3Y
us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
133500000 shares
CY2021Q1 us-gaap Stock Repurchase Program Remaining Authorized Repurchase Amount1
StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
166500000 USD
CY2021Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
27700000 USD
CY2020Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
32100000 USD
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q1 ck0001552033 Numberof Typesof Performance Obligations
NumberofTypesofPerformanceObligations
2
CY2021Q1 us-gaap Profit Loss
ProfitLoss
130600000 USD
CY2020Q1 us-gaap Profit Loss
ProfitLoss
74300000 USD
CY2021Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
2700000 USD
CY2020Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
4100000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
127900000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
70200000 USD
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
190900000 shares
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
189200000 shares
CY2021Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1600000 shares
CY2020Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
3000000.0 shares
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
192500000 shares
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
192200000 shares
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.67
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.37
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.66
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.37
CY2021Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.174
CY2021Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021Q1 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
5800000 USD
CY2021Q1 us-gaap Other Tax Expense Benefit
OtherTaxExpenseBenefit
-5600000 USD
CY2020Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.231
CY2020Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020Q1 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
16200000 USD
CY2020Q1 us-gaap Other Tax Expense Benefit
OtherTaxExpenseBenefit
16200000 USD
CY2020Q1 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2100000 USD
CY2021Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
37700000 USD
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
36900000 USD
CY2021Q1 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
18300000 USD
CY2020Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
18500000 USD
CY2021Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
5100000 USD
CY2020 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
4800000 USD
CY2021Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3 segment
CY2021Q1 ck0001552033 Numberof Corporate Units
NumberofCorporateUnits
1
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
745300000 USD
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
687600000 USD
CY2021Q1 ck0001552033 Segments Adjusted Ebitda
SegmentsAdjustedEBITDA
328800000 USD
CY2020Q1 ck0001552033 Segments Adjusted Ebitda
SegmentsAdjustedEBITDA
289100000 USD
CY2020Q1 ck0001552033 Adjusted Ebitda Adjustment Stockbased Compensation
AdjustedEBITDAAdjustmentStockbasedCompensation
2300000 USD
CY2021Q1 ck0001552033 Adjusted Ebitda Adjustment Corporate Expense
AdjustedEBITDAAdjustmentCorporateExpense
28400000 USD
CY2020Q1 ck0001552033 Adjusted Ebitda Adjustment Corporate Expense
AdjustedEBITDAAdjustmentCorporateExpense
25800000 USD
CY2021Q1 ck0001552033 Adjusted Ebitda Adjustment Net Interest Expense
AdjustedEBITDAAdjustmentNetInterestExpense
25100000 USD
CY2020Q1 ck0001552033 Adjusted Ebitda Adjustment Net Interest Expense
AdjustedEBITDAAdjustmentNetInterestExpense
35800000 USD
CY2021Q1 ck0001552033 Adjusted Ebitda Adjustment Depreciationand Amortization
AdjustedEBITDAAdjustmentDepreciationandAmortization
94300000 USD
CY2020Q1 ck0001552033 Adjusted Ebitda Adjustment Depreciationand Amortization
AdjustedEBITDAAdjustmentDepreciationandAmortization
90300000 USD
CY2021Q1 ck0001552033 Adjusted Ebitda Adjustment Stockbased Compensation
AdjustedEBITDAAdjustmentStockbasedCompensation
16300000 USD
CY2021Q1 ck0001552033 Adjusted Ebitda Adjustment Mergersand Acquisition
AdjustedEBITDAAdjustmentMergersandAcquisition
1800000 USD
CY2020Q1 ck0001552033 Adjusted Ebitda Adjustment Mergersand Acquisition
AdjustedEBITDAAdjustmentMergersandAcquisition
4300000 USD
CY2021Q1 ck0001552033 Adjusted Ebitda Adjustment Accelerated Technology
AdjustedEBITDAAdjustmentAcceleratedTechnology
7300000 USD
CY2020Q1 ck0001552033 Adjusted Ebitda Adjustment Accelerated Technology
AdjustedEBITDAAdjustmentAcceleratedTechnology
2500000 USD
CY2021Q1 ck0001552033 Adjusted Ebitda Adjustment Other
AdjustedEBITDAAdjustmentOther
100000 USD
CY2020Q1 ck0001552033 Adjusted Ebitda Adjustment Other
AdjustedEBITDAAdjustmentOther
35700000 USD
CY2021Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
2700000 USD
CY2020Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
4100000 USD
CY2021Q1 ck0001552033 Adjusted Ebitda Adjustment Total
AdjustedEBITDAAdjustmentTotal
170600000 USD
CY2020Q1 ck0001552033 Adjusted Ebitda Adjustment Total
AdjustedEBITDAAdjustmentTotal
192500000 USD
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
158200000 USD
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
96600000 USD
CY2021Q1 us-gaap Unrealized Gain On Securities
UnrealizedGainOnSecurities
500000 USD
CY2020Q1 ck0001552033 Reimbursement
Reimbursement
100000 USD
CY2021Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
100000 USD
CY2020Q1 us-gaap Legal Fees
LegalFees
30500000 USD
CY2020Q1 ck0001552033 Currencyremeasurement
Currencyremeasurement
4900000 USD
CY2020Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
100000 USD
CY2021Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
3000000.0 USD
CY2020Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
2600000 USD
CY2021Q1 us-gaap Loss Contingency Disclosures
LossContingencyDisclosures
Contingencies<div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal and Regulatory Matters</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are routinely named as defendants in, or parties to, various legal actions and proceedings relating to our current or past business operations. These actions generally assert claims for violations of federal or state credit reporting, consumer protection or privacy laws, or common law claims related to the unfair treatment of consumers, and may include claims for substantial or indeterminate compensatory or punitive damages, or injunctive relief, and may seek business practice changes. We believe that most of these claims are either without merit or we have valid defenses to the claims, and we vigorously defend these matters or seek non-monetary or small monetary settlements, if possible. However, due to the uncertainties inherent in litigation, we cannot predict the outcome of each claim in each instance.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we also are subject to governmental and regulatory examinations, information-gathering requests, investigations and proceedings (both formal and informal), certain of which may result in adverse judgments, settlements, fines, penalties, injunctions or other relief. In connection with formal and informal inquiries by these regulators, we routinely receive requests, subpoenas and orders seeking documents, testimony, and other information in connection with various aspects of our activities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In view of the inherent unpredictability of legal and regulatory matters, particularly where the damages sought are substantial or indeterminate or when the proceedings or investigations are in the early stages, we cannot determine with any degree of certainty the timing or ultimate resolution of legal and regulatory matters or the eventual loss, fines or penalties, if any, that may result from such matters. We establish reserves for legal and regulatory matters when those matters present loss contingencies that are both probable and can be reasonably estimated. However, for certain of the matters described below, we are not able to reasonably estimate our exposure because damages have not been specified and (i) the proceedings are in early stages, (ii) there is uncertainty as to the likelihood of a class being certified or the ultimate size of the class, (iii) there is uncertainty as to the outcome of similar matters pending against our competitors, (iv) there are significant factual issues to be resolved, and/or (v) there are legal issues of a first impression being presented. The actual costs of resolving legal and regulatory matters, however, may be substantially higher than the amounts reserved for those matters, and an adverse outcome in certain of these matters could have a material adverse effect on our consolidated financial statements in particular quarterly or annual periods. We accrue amounts for certain legal and regulatory matters for which losses are considered to be probable of occurring based on our best estimate of the most likely outcome. It is reasonably possible actual losses could be significantly different from our current estimates. In addition, there are some matters for which it is reasonably possible that a loss will occur, however we cannot estimate a range of the potential losses for these matters. </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To reduce our exposure to an unexpected significant monetary award resulting from an adverse judicial decision, we maintain insurance that we believe is appropriate and adequate based on our historical experience. We regularly advise our insurance carriers of the claims (threatened or pending) against us in the course of litigation and generally receive a reservation of rights letter from the carriers when such claims exceed applicable deductibles. We are not aware of any significant monetary claim that has been asserted against us in the course of pending litigation that would not have some level of coverage by insurance after the relevant deductible, if any, is met.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and December 31, 2020, we have accrued liabilities of $79.5 million and $76.0 million, respectively, for anticipated claims. These amounts are included in other accrued liabilities in the consolidated balance sheets. Litigation expense is included in selling, general and administrative expenses in the consolidated statements of income. Legal fees incurred in connection with ongoing litigation are considered period costs and are expensed as incurred.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no new material updates to our legal and regulatory disclosures for the quarter ended March 31, 2021. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Part II, Item 8, Footnote 20, “Contingencies” of our Annual Report on Form 10-K for the year ended December 31, 2020, for a full description of our material pending legal and regulatory matters at that time.</span></div>
CY2021Q1 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
79500000 USD
CY2020Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
76000000.0 USD

Files In Submission

Name View Source Status
0001552033-21-000029-index-headers.html Edgar Link pending
0001552033-21-000029-index.html Edgar Link pending
0001552033-21-000029.txt Edgar Link pending
0001552033-21-000029-xbrl.zip Edgar Link pending
ck0001552033-20210331.htm Edgar Link pending
ck0001552033-20210331.xsd Edgar Link pending
ck0001552033-20210331_cal.xml Edgar Link unprocessable
ck0001552033-20210331_def.xml Edgar Link unprocessable
ck0001552033-20210331_htm.xml Edgar Link completed
ck0001552033-20210331_lab.xml Edgar Link unprocessable
ck0001552033-20210331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tu-20210331ex311.htm Edgar Link pending
tu-20210331ex312.htm Edgar Link pending
tu-20210331ex32.htm Edgar Link pending